This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio
by Moumita C. Chattopadhyay
Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.
Are Medical Stocks Lagging Intuitive Surgical (ISRG) This Year?
by Zacks Equity Research
Here is how Intuitive Surgical, Inc. (ISRG) and biote Corp. (BTMD) have performed compared to their sector so far this year.
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
by Zacks Equity Research
ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
biote Corp. (BTMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Biote Corp. (BTMD) Q1 Earnings Beat Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of 360% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 11.59% and 2.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?
by Zacks Equity Research
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 33.05% and 4.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of 340% and 5.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 58.33% and 3.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Q2 Earnings Meet Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0% and 2.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe biote Corp. (BTMD) Could Rally 44.7%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 44.7% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Recent Price Trend in biote Corp. (BTMD) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, biote Corp. (BTMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does biote Corp. (BTMD) Have the Potential to Rally 82.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for biote Corp. (BTMD) points to an 82.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.